相关临床试验
4
1 进行中
药物批准
14
批准总数
监管机构
1
监管机构数
成立时间
N/A
已完成
2
50.0%
尚未招募
1
25.0%
Unknown
1
25.0%
- The Madras High Court ruled that Venkata Narayana Active Ingredients infringed Novartis AG's Indian patent by exporting large quantities of the diabetes drug Vildagliptin to Egyptian companies between 2016 and 2018. - The court rejected the company's Bolar exception defense under Section 107A of the Patents Act, finding insufficient evidence that exports were solely for research and regulatory purposes. - Justice Senthilkumar Ramamoorthy held that the burden of proof lies on the party invoking Section 107A, construing it as an exception rather than an independent special provision. - The court directed the company to render accounts of profits, pay costs, and recommended the Central Government prescribe documentary requirements for invoking Section 107A.
- Eva Pharma has launched a new oncology and hematology division in Egypt with an annual production capacity of 22 million packages, built to EU-GMP standards to strengthen pharmaceutical self-sufficiency. - Egypt's oncology centers receive approximately 360,000 cancer cases annually, including 80,000 patients under universal health insurance, with treatment costs reaching nearly EGP 13 billion per year. - The facility currently offers seven cancer and immunotherapy drugs in the local market, with plans to introduce 11 additional treatments and expand exports to regional and international markets. - Between 2017 and 2022, Egypt recorded 366,823 cancer cases and 95,275 related deaths, highlighting the critical need for locally manufactured, affordable cancer therapies.
- Nigeria has signed a memorandum of understanding with China's Shanghai Haiqi Industrial Company Limited to establish what Chinese officials describe as Africa's first local insulin production facility. - The initiative aims to end Nigeria's reliance on imported insulin and position the country as a regional hub for medical biotechnology in West Africa. - The project addresses the exponential growth of diabetes on the continent, which is projected to affect almost 60 million people by 2050 compared to 2.5 million estimated cases in 2000. - Local insulin production is expected to reduce treatment costs, create jobs, develop technical expertise, and enhance Nigeria's pharmaceutical manufacturing capacity through technology transfer.
- EVA Pharma signed a strategic cooperation agreement with Qiantang District's BioPharma Town in Hangzhou, establishing its eighth global office to focus on pharmaceuticals, vaccines, and biologics R&D. - The partnership leverages Hangzhou's position as a global leader in Cell and Gene Therapy, with specialized GMP platforms and companies focused on mRNA vaccines, CAR-T therapy, and gene editing. - EVA Pharma will contribute its R&D expertise and regulatory knowledge to explore joint projects in vaccine technology, mRNA applications, and therapeutic biologics while accessing local capabilities. - The collaboration strengthens EVA Pharma's global expansion strategy, building on its existing portfolio across twelve therapeutic areas and operations in over 70 countries worldwide.
• Quantoom Biosciences and TechInvention Lifecare have signed an MoU to collaborate on RNA-based vaccine development, aiming to improve accessibility and affordability in India through Quantoom's N-Force toolbox platform. • TechInvention will establish end-to-end mRNA production capabilities at their upcoming EU-GMP facility in Mumbai, with plans to achieve GMP-ready status for Ntensify midi scale production by late 2025. • The partnership extends beyond human health to animal and environmental applications, featuring environmentally sustainable technology with modular, low-carbon-footprint mRNA systems.
• EVA Pharma, DNA Script, and Quantoom Biosciences forge a groundbreaking partnership to develop the first digital-to-biologics mRNA production platform, targeting 100 million vaccine doses annually. • The collaboration integrates enzymatic DNA synthesis, mRNA production, and formulation technologies to accelerate vaccine development from years to weeks, addressing both human and animal health needs. • This initiative supports Africa CDC's goal of 60% local vaccine production by 2040 and Egypt's target of manufacturing 385 million vaccine doses annually by 2030.
- The Egyptian Drug Authority has approved Lilly and EVA Pharma's human insulin glargine injection for treating type 1 and type 2 diabetes. - This collaboration aims to provide affordable insulin to at least one million individuals in low to middle-income countries, primarily in Africa, annually. - Lilly supplies the active pharmaceutical ingredient at a reduced cost and offers technology transfer to EVA for local insulin formulation and production. - Lilly also licensed baricitinib manufacturing know-how to EVA, enabling the supply of treatments for immunological diseases in 56 LMICs across Africa.
